John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding the resignation of Peter Marks from the FDA: “Under the extraordinary ...

Today, we have details on the National Security Commission on Emerging Biotechnology’s new report—and why tariffs still threaten biotech, including pharma and ag. (816 words, 4 minutes, 4 seconds) ...

While pharmaceuticals were spared the U.S. tariffs that shook world markets last week, the respite could be short-lived. The impact: 94% of biotech firms anticipate surging manufacturing costs from ...

Another busy week begins with BIO’s new survey of member views on tariffs and a BIO Board member’s congressional testimony on how legislation can help small biotechs. (747 words, 3 minutes, 44 seconds ...